METHODS. We conducted a randomized, double-blind, placebo-controlled trial of nebulized 2% lidocaine at 4 mg/kg versus saline placebo during nasogastric tube insertion at a tertiary urban pediatric emergency department. Patients were eligible if they were aged from 1 to 5 years with no comorbid disease and a clinical indication for a nasogastric tube. Nebulization occurred for 5 minutes, 5 minutes before nasogastric tube insertion. Video recordings before, during, and after the procedure were rated using the Face, Legs, Activity, Cry, and Consolability (FLACC) pain and distress assessment tool (primary outcome measure) and pain and distress visual analog scale scores (secondary outcome measures). Difficulty of insertion and adverse events were also assessed.
RESULTS. Eighteen participants were nebulized with 2% lidocaine and 18 participants with normal saline. Nebulization was found to be highly distressing. FLACC scores during nasogastric tube insertion were very high in both groups. There was a trend in the post-nasogastric tube insertion period toward lower FLACC scores in the lidocaine group. Visual analog scale scores for this postinsertion period were significantly lower in the lidocaine arm for pain and distress. There were no significant differences between groups in terms of difficulty of insertion and the number of minor adverse events. The study was terminated early because of the distress and treatment delay associated with nebulization.
CONCLUSIONS. Nasogastric tube insertion results in very high FLACC scores irrespective of lidocaine use. Nebulized lidocaine cannot be recommended as pain relief for nasogastric tube insertion in children. The delay and distress of nebulization likely outweigh a possible benefit in the postinsertion period. Pediatrics 2009; 123:1548 -1555 N ASOGASTRIC TUBE (NGT) insertion is a common pediatric emergency department (ED) procedure. NGT hydration can be effectively used in gastroenteritis, 1 and in some settings it is the primary means of hydration in gastroenteritis and bronchiolitis if oral hydration fails. 2, 3 However, NGT insertion is a very painful procedure. In a study of adult ED patients, 4 NGT insertion was identified by patients and ED staff as the most painful of a number of procedures. When pediatric ED staff rated the pain and distress of 15 common ED procedures on a visual analog scale (VAS), NGT insertion was considered the most distressing and among the most painful. 5 NGTs are currently inserted in many settings, including in our ED, without any form of pain relief beyond a lubricant. 6 There have been a number of randomized, controlled trials (RCTs) in adults that have attempted to find a local anesthetic suitable for use in NGT insertion. [7] [8] [9] [10] [11] [12] The trials have included various combinations of lidocaine, cetacaine, or cocaine nasal or pharyngeal spray; lidocaine nasal gel; and nebulized lidocaine. In a double-blind, placebo controlled, crossover trial with healthy volunteers, 9 nebulized lidocaine resulted in significantly less pain than both sprayed lidocaine and saline placebo. Cullen et al 12 conducted a double-blind, placebo controlled trial in which 50 adult ED patients received either 4 mL of 10% lidocaine solution or saline placebo by nebulizer. On a 100-mm VAS, participants rated a significantly lower discomfort score in the lidocaine group (difference between group means: 21.6 mm [95% confidence interval: 5.3-38.0 mm]). The study did not find that nebulized lidocaine resulted in inadvertent tracheal placement. Subsequent commentaries 13, 14 concluded that, on the basis of these RCTs, it seemed no longer justifiable to perform an NGT insertion in a nonemergency patient without first providing some form of topical anesthesia.
Lidocaine is a cheap, widely available drug with a good safety profile when nebulized. Although topical anesthetics are rapidly absorbed into the circulation after administration onto mucous membranes, raising the possibility of systemic adverse events, 15 blood lidocaine levels after the administration of nebulized lidocaine at normal doses seem low in adults. 16 In an RCT evaluating nebulized lidocaine as an anesthetic for flexible bronchoscopy in children, 17 doses of 4 and 8 mg/kg of 2% lidocaine were well tolerated, with no adverse effects or signs or symptoms of lidocaine toxicity. Blood lidocaine levels were well below toxic levels.
Despite this, we are not aware of any RCTs in children that have evaluated means to reduce pain and distress for NGT insertion in children. We set out to evaluate the efficacy of nebulized lidocaine in reducing pain and distress of NGT insertion in young children.
METHODS

Design and Setting
We conducted a double-blind, randomized, placebocontrolled trial comparing nebulized 2% lidocaine with saline placebo for the relief of pain and distress of NGT insertion in young children. The study was conducted at a tertiary urban pediatric ED with an annual census of 58 000 patients. The study was approved by the hospital ethics committee and was registered with the Australian Clinical Trials Registry.
Study Population
The study population 
Participant Identification
Potential participants were identified by way of researchers monitoring the electronic ED patient registration system or receiving notification from medical and nursing staff.
Exclusion Criteria
Potential participants were excluded if they had an indication for urgent insertion of an NGT, the accompanying adult was non-English speaking and interpreter services were unavailable, they or their parent had an allergy to local anesthetic, or if they had significant comorbid disease, such as asthma, renal or hepatic impairment, epilepsy, cardiac disease, cognitive impairment, or neurologic disease or if the patients had undergone Ͼ1 previous NGT intubation.
Consent
Written, informed consent was obtained from parents or guardians before enrollment. Parent information statements included references to the potential for causing distress during nebulization, the potential of triggering an allergic reaction to lidocaine, and an increased risk of misplacing the nasogastric tube and nose bleeds.
Study Medication
The study drug consisted of vials of either lidocaine hydrochloride (Astra Zeneca, New South Wales, Australia) or 0.9% normal saline placebo. Identically labeled vials were block randomized in groups of 2 and 4 using a computer-generated randomization schedule. Researchers, ED staff, and parents were blinded to the contents of each vial, which were known only to the pharmacy department.
The volume of study drug (either 2% lidocaine or placebo) delivered was calculated based on a dose equivalent of 4 mg/kg of lidocaine. This dose, when nebulized, was found in a study by Gjonaj et al 17 to be safe and well tolerated in young children undergoing flexible bronchoscopy. The study drug was then made up to 5 mL with normal saline for nebulization delivery. The lidocaine concentration of the nebulized solution was, therefore, variable and weight dependent.
Outcome Measures
Primary
The primary outcome measure for the study was the Face, Legs, Activity, Cry, and Consolability (FLACC) score. FLACC has been recommended as a procedural pain score for preverbal and early verbal children in 2 recent reviews by von Baeyer and Spragrud 18 and Crellin et al. 19 The FLACC score is a behavioral scale originally designed to score postoperative pain in young children. It also captures behaviors related to distress unrelated to pain. 20 FLACC is composed of 5 separate items: face, legs, activity, cry, and consolability. Each of these items is scored on a range of 0 to 2 and then added for a total FLACC score of 0 to 10 ( Table 1) .
Secondary
Secondary outcome measures included 100-mm VASs for pain and distress, vital sign measurements, and clinical information from the intubation. In addition, the nurse who inserted the NGT rated the difficulty of insertion on an ordinal scale from 1 to 5, where 5 is the most difficult insertion. The number of attempts required to successfully insert the NGT, the method used to confirm correct NGT positioning, and any adverse events or changes in vital signs were also recorded.
Procedure
The study procedure was divided into 6 phases: initial observation, nebulization of study drug, rest, restraint, NGT insertion, and postinsertion (Fig 1) . Vital signs were measured as per Fig 1. In addition, the patient was monitored for arrhythmias by way of 3-lead cardiac monitoring.
The study drug was administered over 5 minutes via an Aerflo jet nebulizer (Unomedical, New South Wales, Australia) with a flow rate of 8 L/min and applied to the participant's face while held in a position of comfort. If this action caused unacceptable distress, the mask was placed below the level of the face and angled to allow the participant to inhale the vapor.
Five minutes after nebulization, the patient was restrained supine on the procedure trolley, and a lubricated NGT was inserted according to standard ED practice. Confirmation of tube placement was achieved by aspiration of gastric contents and testing of the aspirate pH.
After insertion of the NGT, the participant was observed for 5 minutes. After completion of the procedure and the recovery period, parent/guardians and nurses were asked for a retrospective assessment of the pain and distress of nebulization and NGT insertion using VAS pain and VAS distress (Fig 1) .
Filming, Processing, and Rating of Recordings
The entire procedure was filmed by a researcher, and each digital recording was spliced into 6 clips along predefined boundaries (Table 2 ) and inserted into a database. Clips were evaluated by 2 experienced ED staff members, an ED attending physician and a nurse practitioner, who independently determined FLACC, VAS pain, and VAS distress scores using a purpose-built evaluation database. The database placed the clips nonse- Nebulized lidocaine versus placebo for NGT insertion: study flowchart. a Note that nurse and parent VAS pain and VAS distress were assessed retrospectively after completion of the procedure.
quentially and presented a clip evaluation interface for the evaluators. Although evaluators watched the entire clip, the section that they considered for evaluation was less than the whole clip for some time periods, as defined in Table 2 .
Statistical Analysis
The researchers aimed to recruit 52 participants for the study, with 26 in each arm. The sample size was based on a conservative estimate of SD of FLACC scores, 2.5, derived from an earlier pilot study of NGT insertions conducted in our department. 21 This sample size would give an 80% chance to detect a 2-point and 20-mm difference in mean FLACC or mean VAS scores, respectively, using a 2-sided, 2-group t test with a significance level of ␣ ϭ .05. Although a similar difference in FLACC has been assumed to represent a clinically significant difference in another study, 22 there are no actual studies denoting what represents a clinically significant difference in FLACC scores. In the absence of specific literature, a 2-point difference in mean FLACC scores was assumed to represent a clinically significant difference. Similarly, based on previous data indicating that VAS scores with 24 mm of mean difference were perceived as clinically different by pediatric patients, 23 a 20-mm difference was assumed to represent a clinically significant difference. FLACC and VAS scores from the 2 ED clinicians were averaged for further analysis by using Stata 10.0 (Stata Corp, College Station, TX). FLACC scores and VAS scores are presented as median and interquartile range (IQR). Nonnormally distributed scores were compared using a Wilcoxon rank-sum test and normally distributed data using a t test. Categorical data were analyzed using a Fisher's exact test. To illustrate differences in FLACC and VAS scores, the median difference in scores and associated confidence intervals were also calculated using a Hodges-Lehmann estimate of shift. 24 
RESULTS
During the study period, there were an estimated 388 patients between 1 and 5 years of age who received an NGT at the our ED. Research staff approached 84 of these families and deemed 17 patients ineligible, mainly because of comorbid diseases (Fig 2) . Twenty-nine families declined to participate, mainly because of concerns regarding the distress, delay, and safety associated with lidocaine nebulization (Fig 2) . Thirty-eight participants were enrolled and randomly assigned. Two withdrawals occurred within the lidocaine arm, 1 during baseline vital sign measurement and 1 during nebulization, because of the distress caused by the assessment of vital signs and nebulization, respectively. Thus, 18 patients in the lidocaine arm and 18 in the placebo arm completed the study and represent the study sample (Fig 2) . The study was terminated early before enrolling the planned 52 patients because of researcher and ED nursing staff concerns about the level of distress experienced by patients during nebulization.
Baseline Characteristics
Baseline characteristics of the lidocaine and placebo groups (Table 3) were similar. The difference of note was gender distribution, with two thirds of lidocaine participants being male and only one third of placebo participants being male.
Comparison of Video Recordings
FLACC scores, the primary outcome measure of the study, were analyzed using an average of the scores of 2 senior ED clinicians (Fig 3) . Irrespective of agent used, a broad pattern of FLACC scores emerged, with a peak score during nebulization (lidocaine median: 6. On analysis, FLACC data were not normally distributed. Primary analysis was computed, therefore, by Wilcoxon rank-sum test. There was no statistically significant difference between lidocaine and placebo groups in FLACC scores at any time period (Table 4) . Secondary analysis assuming normal distribution and comparing means using a t test also did not indicate a statistically significant difference between groups at any time period. There was a statistically significant difference for both VAS pain (P ϭ .01) and VAS distress (P ϭ .02) by Wilcoxon rank-sum test only in the postinsertion phase (Table 5) . However, there was no other significant difference between groups in the distress or pain scoring of nebulization or NGT insertion, as assessed by either nurses or parent/guardians.
TABLE 2 Nebulized Lidocaine Versus Placebo for NGT Insertion: Boundaries of Clips and Boundaries for Evaluation
Clip
Boundary of Film Clips Evaluation of Distress and Pain
Adverse Events
There was no significant difference in adverse events between groups (adverse events versus no adverse events, P ϭ 1.00). Confidence intervals for mean difference in adverse events between lidocaine and placebo groups were calculated using a 2-sample test of proportion (Table 6 ). Mild self-terminating epistaxis was the most frequent adverse event.
One participant in the lidocaine arm experienced a brief endotracheal placement detected by the procedure nurse. The NGT was reinserted with gastric placement during the study period.
In the placebo arm, 1 patient experienced an endotracheal intubation detected on chest radiograph, because no gastric aspirate could be obtained. The NGT was removed and later successfully inserted without sequelae. An esophageal intubation was detected by chest radiograph when an aspirate could not be obtained. An NGT was successfully inserted after the study period.
One NGT could not be inserted in the lidocaine group based on 3 unsuccessful attempts. The participant was later able to tolerate fluids orally. The second failed insertion involved a participant in the placebo arm after 4 unsuccessful attempts. The participant was ultimately rehydrated by intravenous access.
Overall, there were no statistically significant differences by Wilcoxon rank-sum tests in vital signs between both groups, with the exception of diastolic blood pressure during nebulization, found to be statistically, although not clinically, significantly lower in the lidocaine group (P ϭ .04). There were no arrhythmias detected at any point. Vital signs could not be obtained in all of the patients because of high levels of patient distress during nebulization.
DISCUSSION
This is the first trial to attempt to reduce the pain and distress of NGT insertion in children. On analysis of researcher FLACC scores, the primary outcome measure, nebulization of lidocaine, did not decrease pain and distress during NGT insertion as compared with placebo. Researcher VAS scores for pain and distress scores also failed to show a difference between groups during insertion. There was a trend for FLACC scores to be lower in the lidocaine group during the postinsertion recovery period. This difference was not found to be statistically significant, but if the study had been continued and had enrolled the intended 52 patients, this may have shown a statistical difference. Two secondary outcomes, researcher VAS for pain and VAS for distress, were both significantly lower in the lidocaine group during the postinsertion time period, and procedure nurses rated the NGT insertion overall as being less painful for the lidocaine group (P ϭ .05).
However, we found that, in our sample of young children (mean age: 1.8 years), nebulization was much more distressing than anticipated. Nebulization was evaluated by researchers with a median FLACC score of 6.3 and a median VAS distress score of 42 mm. The ability of children to tolerate nebulization varied widely, as indicated by wide spreads of IQR in FLACC and VAS distress scores. The high distress scores during nebulization are similar to results of a survey of ED staff perceptions of patient distress during nebulization. 5 Although it may reduce the pain and distress of the recovery period after NGT insertion, this does not warrant the additional delay and distress associated with nebulization. Based on our data, nebulized lidocaine cannot be recommended as a means to reduce the pain and distress of NGT insertion in children. This is in contrast to adult studies, where nebulized lidocaine was recommended as an anesthetic for NGT insertion after it was shown effective in reducing the associated pain and discomfort. 9, 12, 13 Although a sample size of 52 participants was planned, the study was prematurely ended after 38 participants were recruited. The key reason for this decision was the researchers' and ED nursing staff's concern about the distress of nebulization. Consequently, researchers also found a high level of difficulty in recruiting participants, because this concern was shared by parents. In addition, there was ongoing apprehension about the delay to NGT insertion because of the study procedures. The premature end to the study may lead to it being less powerful than originally intended and may increase the possibility of a type II error. However, the universally very high FLACC and VAS scores with tight IQRs argue for a true lack of efficacy during NGT insertion.
Similar to a study on nebulized lidocaine for bronchoscopy, 17 the study findings indicate that 4 mg/kg of nebulized lidocaine seem safe in previously healthy children aged 1 to 4 years. A significant decrease in expiratory flow and increased airway resistance had been found in patients with reversible obstructive lung disease after nebulized lidocaine was administered compared with baseline or placebo values. 25 We excluded patients with asthma, and we did not encounter clinically apparent reactive airway disease associated with nebulization.
There was no evidence that nebulized lidocaine altered the number of attempts required, the difficulty of NGT insertion, or the incidence of adverse events. This was in contrast to the study by Cullen et al, 12 where nebulized lidocaine for NGT insertion in adults was associated with an increased incidence of epistaxis. Nebulized lidocaine anesthetized the upper airway, thereby potentially removing natural airway protection against aspiration and exposing the patient to an increased risk of misplacement of the tube. Although we did not find clinically apparent aspiration or an increased rate of airway placement of the NGT, we cannot exclude silent aspiration.
We confirmed previous findings in adults 4 and children 5 that NGT insertion is very distressing and painful irrespective of study drug or placebo use. This reaffirms the importance of finding a method of pain and distress relief that is effective and feasible for NGT insertion. Lidocaine nasal and pharyngeal spray may be easier, quicker, and less distressing to administer but may induce a more modest effect than when administered by a nebulizer. 9 The study found higher rates of both NGT repeat insertion attempts and adverse events compared with previous data, 6, 26, 27 likely because of the more rigorous, prospective reporting and recording of adverse events and reinsertions.
LIMITATIONS
In addition to the early termination, the study had a number of limitations. The results of the study only apply to children aged 1 to 5 years with no comorbid disease. Although FLACC has been recommended for procedural use by 2 reviews of literature 18, 19 and has been used for measuring procedural pain and distress in studies, 20, [28] [29] [30] [31] [32] it has not yet been specifically validated for this purpose. Also, FLACC scores frequently reached their maximum value of 10 during NGT insertion, which reduced their ability to discriminate during highly distressing or painful phases of the procedure. The FLACC scale scored behaviors that were sometimes partially not applicable for the video clip being evaluated; for example, consolability was difficult to assess if the child was not actively consoled. Although study protocol and ED guideline for NGT insertion were standardized, there was some variation in terms of nurses' comfort and CI indicates confidence interval; -, no patients with this condition. a Endotracheal placement was noted clinically and reinserted correctly during the study. b Endotracheal placement was noted on chest radiograph and reinserted correctly after the study. c Esophageal placement was noted on chest radiograph and reinserted correctly after study.
